Mesude Angın
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mesude Angın has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Ayse Caner
Department of Basic Oncology, Institute of Health Sciences, Ege University
2 shared publications - Adriano Casulli
European Union Reference Laboratory for Parasites (EURL-P), Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
1 shared publication Ayşegül Ünver
Ege University Faculty of Medicine, Department of Medical Parasitology, İzmir, Türkiye
1 shared publication- Ayşegül Ünver
Ege University, Faculty of Medicine, Department of Parasitology, Izmir, Turkey
1 shared publication - Carlos Sánchez-Ovejero
Instituto de Recursos Naturales y Agrobiología de Salamanca (IRNASA-CSIC), Salamanca, Spain
1 shared publication Cumhur Gunduz
Faculty of Medicine, Department of Medical Biology, Ege University, Izmir, Turkey
1 shared publication
Latest Publications
- 3 September 2026
- Published by Raw Data Library
Identification of the mutations occurring in the 'deoxy adenosine' region of the hepatocyte growth factor (HGF) gene promoter in hepatocellular carcinoma and the role of these mutations in the development of sorafenib resistance
Objective: Hepatocyte Growth Factor (HGF) is known to increase expression as in other cancer types. This study aimed to investigate expression at the transcriptional level of HGF expression. Because of this, we examined the presence of mutation in the hepatocellular carcinoma cells in the region of 30 reprocessed deoxyadenosine in the HGF promoter and found that it was related to high HGF levels Method: Two hepatocellular carcinoma cell lines and two human genomic DNA lines were used in this study. Genomic DNAs were obtained with the aid of kit and region specific primers were designed and amplified. Next, bi-directional Sequencing was done. Chromatogram data showed deoxy adenosine levels in the region. Subsequently, the present HGF expressions in these cells were compared with our data Results: When HGF mutations were normal in some hepatocellular carcinoma cells, shortening in DATE region was observed in nascent cell lines, and it was determined that the number of deoxyadenosine in the DATE region was normal in cells with high autocrine HGF expression Conclusion: HGF is responsible for the activation of autocrine HGF in the DATE region due to its transcription in some cancer types. Our results suggest that methylation levels should be examined in cell lines where the DATE region is normal and shortened in order to understand the role of HGF DATE region in expression
- 3 September 2026
- Published by Raw Data Library
Identification of the mutations occurring in the 'deoxy adenosine' region of the hepatocyte growth factor (HGF) gene promoter in hepatocellular carcinoma and the role of these mutations in the development of sorafenib resistance
Objective: Hepatocyte Growth Factor (HGF) is known to increase expression as in other cancer types. This study aimed to investigate expression at the transcriptional level of HGF expression. Because of this, we examined the presence of mutation in the hepatocellular carcinoma cells in the region of 30 reprocessed deoxyadenosine in the HGF promoter and found that it was related to high HGF levels Method: Two hepatocellular carcinoma cell lines and two human genomic DNA lines were used in this study. Genomic DNAs were obtained with the aid of kit and region specific primers were designed and amplified. Next, bi-directional Sequencing was done. Chromatogram data showed deoxy adenosine levels in the region. Subsequently, the present HGF expressions in these cells were compared with our data Results: When HGF mutations were normal in some hepatocellular carcinoma cells, shortening in DATE region was observed in nascent cell lines, and it was determined that the number of deoxyadenosine in the DATE region was normal in cells with high autocrine HGF expression Conclusion: HGF is responsible for the activation of autocrine HGF in the DATE region due to its transcription in some cancer types. Our results suggest that methylation levels should be examined in cell lines where the DATE region is normal and shortened in order to understand the role of HGF DATE region in expression
- Open Access
- 9 May 2025
- Published by Galenos Yayinevi in Turkish Journal of Parasitology
- Vol. 49 (1) , 23-28
Evaluation of miR-146a Expression Levels in Archived Serum Samples for the Diagnosis/Follow-up of Patients with Cystic Echinococcosis
Evaluation of miR-146a Expression Levels in Archived Serum Samples for the Diagnosis/Follow-up of Patients with Cystic Echinococcosis - Turkish Journal of Parasitology
- 9 May 2025
- Published by Galenos Yayinevi in Turkish Journal of Parasitology
- Vol. 49 (1) , 23-28
Open AccessEvaluation of miR-146a Expression Levels in Archived Serum Samples for the Diagnosis/Follow-up of Patients with Cystic Echinococcosis
Evaluation of miR-146a Expression Levels in Archived Serum Samples for the Diagnosis/Follow-up of Patients with Cystic Echinococcosis - Turkish Journal of Parasitology
- 7 March 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-11
Effects of 5-azacytidine and N6-methyladenosine combination on apoptosis and stemness in human breast cancer stem cells
Background This study investigates the combined effects of the epigenetic anticancer drug 5-azacytidine (5-Aza) and N6-methyladenosine (m6A) on breast cancer stem cells (CSCs) and normal breast epithelial cells. CSCs are characterized by their ability to self-renew, their resistance to conventional therapies, and their role in metastasis, presenting a significant challenge in breast cancer treatment. Methods and results The study utilized flow cytometry to isolate CD44 + /CD24low CSCs from MCF-7 breast cancer cells and evaluated these cells through spheroid formation assays. The results demonstrated that both 5-Aza and m6A, both individually and in combination, exert cytotoxic effects on CSCs, induce apoptosis, and reduce their migratory capacity. Importantly, these treatments did not produce similar effects on normal breast epithelial cells (MCF-10A), indicating selective action on CSCs. Gene expression analysis revealed that treatment with 5-Aza, m6A, and their combination altered the expression of key stem cell-related genes, including OCT4, NANOG, SOX2, and c-MYC, which are associated with CSC self-renewal and malignancy. Conclusions These findings suggest that epigenetic modulation through 5-Aza and m6A could effectively target CSCs, disrupting their ability to drive tumor progression and metastasis, particularly in aggressive breast cancer subtypes. This study highlights the potential of 5-Aza and m6A as a combinatorial therapeutic approach, offering a promising avenue for improving treatment outcomes in breast cancer patients, especially those with therapy-resistant disease. Further clinical investigation is needed to validate these findings and explore their therapeutic implications. Graphical abstract
- 7 March 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-11
Effects of 5-azacytidine and N6-methyladenosine combination on apoptosis and stemness in human breast cancer stem cells
Background This study investigates the combined effects of the epigenetic anticancer drug 5-azacytidine (5-Aza) and N6-methyladenosine (m6A) on breast cancer stem cells (CSCs) and normal breast epithelial cells. CSCs are characterized by their ability to self-renew, their resistance to conventional therapies, and their role in metastasis, presenting a significant challenge in breast cancer treatment. Methods and results The study utilized flow cytometry to isolate CD44 + /CD24low CSCs from MCF-7 breast cancer cells and evaluated these cells through spheroid formation assays. The results demonstrated that both 5-Aza and m6A, both individually and in combination, exert cytotoxic effects on CSCs, induce apoptosis, and reduce their migratory capacity. Importantly, these treatments did not produce similar effects on normal breast epithelial cells (MCF-10A), indicating selective action on CSCs. Gene expression analysis revealed that treatment with 5-Aza, m6A, and their combination altered the expression of key stem cell-related genes, including OCT4, NANOG, SOX2, and c-MYC, which are associated with CSC self-renewal and malignancy. Conclusions These findings suggest that epigenetic modulation through 5-Aza and m6A could effectively target CSCs, disrupting their ability to drive tumor progression and metastasis, particularly in aggressive breast cancer subtypes. This study highlights the potential of 5-Aza and m6A as a combinatorial therapeutic approach, offering a promising avenue for improving treatment outcomes in breast cancer patients, especially those with therapy-resistant disease. Further clinical investigation is needed to validate these findings and explore their therapeutic implications. Graphical abstract
- Open Access
- 1 January 2022
- Published by Elsevier in Acta Tropica
- Vol. 225, 106208
Comparison of the multi-epitope recombinant antigen DIPOL and hydatid fluid for the diagnosis of patients with cystic echinococcosis
- 1 January 2022
- Published by Elsevier in Acta Tropica
- Vol. 225, 106208
Open AccessComparison of the multi-epitope recombinant antigen DIPOL and hydatid fluid for the diagnosis of patients with cystic echinococcosis